← All trials
NCT05097651
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Oct 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Oct 28, 2021
- Last posted
- Oct 28, 2021
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San DiegoLead sponsor
- University of California, San DiegoSponsor investigator
- University of California, San DiegoOverall official - principal investigator
- National Institute on Drug Abuse (NIDA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.